Gerresheimer stock holds after 2026 guidance pressure

Gerresheimer (ISIN DE000A0LD6E6) is anchored by fiscal 2025 revenue of EUR 2.04 billion and adjusted EBITDA of EUR 433.2 million, while the company has guided to 2026 revenue growth of around 3% to 5% and adjusted EBITDA growth of around 4% to 6%. Those figures frame Gerresheimer stock for investors even without a fresh market quote in this call.

EUR 2.04 billion revenue

Fiscal 2025 revenue reached EUR 2.04 billion, up 14.2% year on year, according to the companys 2025 reporting context. Adjusted EBITDA came in at EUR 433.2 million, which implies an adjusted EBITDA margin of 21.2% for the year.

The comparison matters because the 14.2% revenue increase and the 21.2% margin give a clearer baseline than a simple business description. For Gerresheimer stock, the question is whether the 2026 growth plan can sustain that profitability profile.

2026 guidance stays central

Gerresheimer has pointed to 2026 revenue growth of around 3% to 5% and adjusted EBITDA growth of around 4% to 6%, a slower pace than the 2025 top-line expansion. That makes the margin path more important than pure volume growth.

For investors, the quantified comparison is straightforward: 2025 revenue rose 14.2%, while 2026 guidance now points to mid-single-digit growth. The stock response typically hinges on whether the market sees that as a normalization after a strong prior year or as a step down in momentum.

Margin still decides

Adjusted EBITDA of EUR 433.2 million in fiscal 2025 is the key operating number to watch against the 2026 guidance range. If the company reaches the upper end of the EBITDA growth corridor, the margin base can stay resilient even with slower sales growth.

That is the main investment lens for Gerresheimer stock: revenue growth, EBITDA growth, and the implied margin spread versus fiscal 2025. The 2025 base of EUR 2.04 billion in revenue and EUR 433.2 million in adjusted EBITDA leaves a clear benchmark for the next report cycle.

Packaging drives the mix

Gerresheimer sells packaging and containment solutions for pharmaceuticals, including specialty glass and plastic packaging as well as delivery systems. Those product lines matter because the mix of pharma packaging and delivery solutions influences both revenue quality and margin stability.

When revenue grows at 3% to 5% in 2026 after a 14.2% rise in 2025, product mix becomes more important than headline scale. A higher share of specialty solutions can support the adjusted EBITDA path if pricing and utilization remain favorable.

Market level and closing view

In this call, no verified live share price or market capitalization was available to anchor a fresh quote line, so the most relevant dated market context is the fiscal 2025 base and the 2026 guidance range. Gerresheimer stock therefore reads as a numbers-led story rather than a headline-driven move.